Phase II trial of piroxantrone in metastatic gastric adenocarcinoma

Piroxantrone, a synthetic intercalating agent, was studied in patients with advanced, measurable gastric adenocarcinoma who had not received prior chemotherapy. The starting piroxantrone dose was 150 mg/m2 given intravenously over 1 hour on day 1 and repeated every 21 days. Response and toxicity cou...

Full description

Saved in:
Bibliographic Details
Published inInvestigational new drugs Vol. 12; no. 3; p. 263
Main Authors Pazdur, R, Bready, B, Scalzo, A J, Brandof, J E, Close, D R, Kolbye, S, Winn, R J
Format Journal Article
LanguageEnglish
Published United States 01.01.1994
Subjects
Adenocarcinoma - drug therapy
Adult
Aged
Aged, 80 and over
Anemia - chemically induced
Anthraquinones - adverse effects
Anthraquinones - therapeutic use
Antineoplastic Agents - therapeutic use
Fatigue - chemically induced
Female
Humans
Male
Middle Aged
Neoplasm Metastasis
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Stomach Neoplasms - drug therapy
Vomiting - chemically induced
Online AccessGet more information

Cover

More Information
Summary:Piroxantrone, a synthetic intercalating agent, was studied in patients with advanced, measurable gastric adenocarcinoma who had not received prior chemotherapy. The starting piroxantrone dose was 150 mg/m2 given intravenously over 1 hour on day 1 and repeated every 21 days. Response and toxicity could be evaluated in 15 patients. No complete, partial, or minor responses were observed. Toxic effects included granulocytopenia, anemia, vomiting, nausea, anorexia, fatigue, stomatitis, alopecia, hyperbilirubinemia, and increased alkaline phosphatase levels. At the stated dose and schedule, piroxantrone does not possess significant activity against advanced gastric cancer.
ISSN:0167-6997
DOI:10.1007/BF00873970